Caption Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Caption Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-9,000	Closed	-$640K	–	1542
2022 Q1	$640K	Buy	+9,000	New	+$586K	0.01%	1098
2020 Q4	–	Sell	-23,000	Closed	-$1.05M	–	1052
2020 Q3	$1.05M	Buy	23,000 +10,000	+77%	+$485K	0.02%	598
2020 Q2	$652K	Buy	+13,000	New	+$673K	0.02%	633
2019 Q4	–	Sell	-10,000	Closed	-$600K	–	879
2019 Q3	$600K	Hold	10,000	–	–	0.03%	465
2019 Q2	$844K	Buy	+10,000	New	+$900K	0.04%	400

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Caption Management's ENTA Position: Q2 2022 in Review

Caption Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2022, closing a stake of 9,000 shares — an estimated $640K sold.

Caption Management first reported a position in ENTA in Q2 2019 and held it in 5 quarters. The position peaked at $1.05M in Q3 2020. 154 funds tracked by Wall St. Rank hold ENTA as of Q2 2022.

Caption Management reported no remaining Enanta Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Caption Management sold 9,000 Enanta Pharmaceuticals shares in Q2 2022, an estimated $640K.
Caption Management first reported a position in Enanta Pharmaceuticals in Q2 2019 and held it in 5 quarters.
Caption Management's Enanta Pharmaceuticals position peaked at $1.05M in Q3 2020.
154 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2022.

Based on Caption Management's 13F filing for Q2 2022, filed 15 Aug 2022.